The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.
A high-profile House Select Committee hearing has highlighted the United States' critical dependence on Chinese active pharmaceutical ingredients (APIs). Lawmakers warn that Beijing is applying its successful industrial playbook from rare earths and EVs to corner the global medicine market, with Chinese pharma revenue projected to hit $2.1 trillion by 2030.
Tencent CEO Pony Ma has admitted the tech giant was "slow" to react to the generative AI revolution, contrasting with the aggressive multi-billion dollar investment strategies of rivals Alibaba and ByteDance. This divergence marks a critical juncture for Chinese Big Tech as they navigate varying capital expenditure paths in the global race for AI dominance.
Tencent CEO Pony Ma has admitted the social media giant was "slow" to react to the AI revolution, signaling a conservative approach compared to rivals. While Alibaba and ByteDance commit hundreds of billions to aggressive AI expansion, Tencent’s "measured pace" highlights a growing strategic divide among China's technology leaders.